NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 10 Aug 2021 (#25)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit **www.grants.nih.gov** or **www.sun.ac.za/RDSfunding** (current & archive).*

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- PA-20-196 NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

NOT-OD-21-169 New NIH "FORMS-G" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2022. This notice informs the applicant and recipient communities of changes to grant application forms and application guide instructions for due dates on or after **25 January 2022**.
The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- SF424 R&R
- R&R Senior/Key Person Profile (Expanded)
- R&R Budget and Associated Subaward Budget Attachment(s) Form
- Project/Performance Site Location(s)
- PHS 398 Training Budget and Associated Subaward Budget Attachment(s) Form
- PHS Additional Indirect Costs
- PHS Fellowship Supplemental Form
- PHS Human Subjects and Clinical Trials Information

- As part of the federal-wide transition from the DUN and Bradstreet (D&B) Data Universal Numbering System (DUNS) number to the new government-owned Unique Entity Identifier (UEI), applicants will be required to have a UEI to apply for federal grants or cooperative agreements. The System for Award Management (SAM) will become the central repository for the new UEI that will be incorporated into an institution's SAM registration. Although agencies are not required to fully transition until April 2022, NIH, AHRQ, and FDA will transition for due dates on or after January 25, 2022 to align with standard application and review cycles. See NOT-OD-21-170 for more information.

- NIH will require the use of the updated Biographical Sketch and Other Support format pages for submissions on or after January 25, 2022. See NOT-OD-21-073, NOT-OD-21-110, and NOT-OD-21-122 for more information.
- Targeting due dates on or after January 25, 2022, all Senior/Key personnel listed on the R&R Senior/Key Person Profile (Expanded) form will be required to have an eRA Commons username (Commons ID). Extension of the existing eRA Commons ID requirement to include all senior/key personnel will facilitate better data collection for individuals contributing to federally funded research as well as assist in disambiguating data on applications and facilitating the identification of conflicts of interest in peer review. See NOT-OD-21-109 for more information.

NOT-OD-21-172 Adjusted Timeline for Requiring Two-Factor Authentication to Access eRA Modules Using Login.Gov or InCommon Federated Accounts. The deadline and approach to requiring two-factor authentication (also known as multi-factor authentication) to increase the security when accessing eRA modules (eRA Commons, Commons Mobile, ASSIST, Internet Assisted Review) are changing. NIH is providing more time to make the transition. Instead of requiring all users to transition to Login.gov by a fixed deadline of September 15, eRA will begin a phased approach beginning September 15,2021 for enforcing the two-factor authentication requirement for the NIH recipient community as described below. In this phased approach to enforcement, all scientific account holders should take action now, while administrative account holders will be required to move to two-factor authentication in early calendar year 2022

NOT-AI-21-073 Notice of Participation of the National Institute of Allergy and Infectious Diseases (NIAID) in PAR-21-248 Pediatric Immune System – Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed). This Notice is to inform potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective immediately. In addition to the NICHD Research Scope, NIAID interests include:

- HIV research studies that include animal models may only use non-human primates
- Mechanisms regulating the generation and maintenance of B and T cell memory
- Molecular mechanisms of innate immunity, including trained immunity
- Mechanisms of tissue/organ-specific and mucosal immunity
- Epigenetic and/or metabolic regulation of the immune response
- Role and mechanisms of action of immune potentiators for understanding and improving early immune functionality
- Impact of maternal factors on immune system development and functioning in early life that include examination of longer-term effects in children
- Immunological correlates that modify/influence the host response to viral respiratory infections
- Impact of viral infection on the development of the immature immune system
- Impact of early life respiratory infection on subsequent infections.

NOT-DA-21-069 **Notice to Extend the Expiration Date for PAR-19-162, "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)"** The purpose of this notice is to inform interested applicants that the expiration Date for PAR-19-162 , "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)" will be extended by one Council round (changes shown in bold italics below). This Funding Opportunity Announcement has been modified to add an additional Application due date of **October 5, 2021** ***(new applications), November 5, 2021 (resubmission applications)*** **and an additional AIDS Application Due Date of January 7, 2022.**

NOT-HD-21-042 Notice of Intent to Publish a Funding Opportunity Announcement for Reissue of Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional). The purpose of this Notice is to inform the scientific community that the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) plans to reissue Funding Opportunity Announcement (FOA) RFA-HD-21-006, "Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional)" with the following important change: the maximum project **period will be 4 years** instead of 5 years. The Specific Areas of Research Interest to this FOA will be the same as RFA-HD-21-006.

NOT-AI-21-067 Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes. The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that

applies somatic cell gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from clinical use. This notice applies to due dates on or after **October 5, 2021** and subsequent receipt dates through **September 7, 2024**. The following funding opportunity announcements (FOAs) or their reissued equivalents must be used for submissions for this initiative. Although NHLBI is not listed as a Participating Organization in all the FOAs listed below, applications for this initiative will be accepted.

- PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

NOT-DE-21-010 Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions. Diagnosing and treating lesions of the oral cavity and oropharynx are challenging due to reliance on subjective analyses of clinical features and histopathological diagnostic criteria. High resolution and quantitative tools are needed to enhance the precision of diagnostic approaches for oral pathologies to guide options for treatment. This Notice of Special Interest (NOSI) is to encourage research projects that develop, adapt, optimize, and validate imaging-based applications and data analysis tools to enhance oral disease detection, diagnosis, and treatment. The long-term goal is to facilitate translation of research findings into clinical practice, paving the way for personalized health care through objective measures that promote accurate and timely diagnosis, targeted therapies, and improved patient survival and quality of life. This notice applies to due dates on or after October 5, 2021, and subsequent receipt dates through September 10, 2024.
Submit applications for this initiative in response to one of the following funding opportunity announcement (FOA) or the subsequent reissued equivalent through the expiration date of this notice:

- PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-195- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

NOT-DK-21-024 Notice of Special Interest: Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders. Gastrointestinal (GI) complications in children and adults with neurodevelopmental disorders have drawn attention to gaps in understanding their causes and treatment. GI dysfunction is particularly common in individuals with neurodevelopmental disorders such as autism, Fragile X syndrome, and Rett syndrome, as well as chromosomal disorders such as Down syndrome. This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through July 16, 2024.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

- PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

Funding Opportunity Announcements (FOA)

1. Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-21-303** **Type: R21/R33**
Application Due Date: November 15, 2021, November 15, 2022. **Aids Dates:** December 09, 2021December 09, 2022. Apply by 5:00 PM local time of applicant organization
Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. This FOA provides support for up to two years (R21 phase) for technology development and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. All applicants must address both the R21 and R33 phases.
Budget: The R21 phase may not exceed $125,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed $200,000 in direct costs in any single year of the R33 phase. The project period is limited to 2 years for the R21 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

2. Imaging - Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-21-309** **Type: R03**

Application Due Date: Standard dates and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.

Budget: Applicants may request direct costs of up to $150,000 for a period of one year only. The maximum project period is 1 year.

3. Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-21-310** **Type: R03**

Application Due Date: Standard dates and Standard AIDS dates apply. The first standard due date for this FOA is Oct 5,2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.

Budget: Budgets for direct costs of up to $150,000 per year and is for a period of one year only. The maximum project period is 1 year.

4. Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD and its Progression (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-22-023** **Type: R01**

Application Due Date: October 22, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Recent findings have raised the hypothesis that systemic immune responses could play direct or indirect roles in brain neurodegeneration leading to AD/ADRD and have been significantly less studied than immune responses confined exclusively to within the brain parenchyma. The purpose of this funding opportunity announcement (FOA) is to support partnerships and new collaborations between neuroscientists and immunologists to expand the research base in this area with the long-term goal of bringing more immunology expertise into the AD/ADRD field and to support further work in this area through investigator-initiated and other mechanisms.

Budget: NINDS intends to commit $3,750,000 in total costs per year in FY2022-2027 to fund up to five awards contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project. The maximum project period is five years.

5. Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Production Research and Development Centers (UMI Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: RFA-HG-21-029** **Type: UM1**

Application Due Date: November 1, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This FOA is one of three issued to create a new program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase 1 will also assess the scale limitations of such methods, develop common data formats, establish “use cases” for this catalog, and inform whether and how a potential second phase will be implemented. This specific FOA seeks applications for MorPhiC Data Production Research and Development Centers, which will develop diverse systems and assays and explore and compare approaches to produce MorPhiC data at scale, and to maximize its informativeness.

Budget: NHGRI intends to commit $7M total in FY 2022 to fund 4-5 awards. Application budgets must not exceed $1.1M direct costs per year. The maximum project period is five years.

6. Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: RFA-HG-21-030** **Type: U01**

Application Due Date: November 1, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This FOA is one of three issued to create a new program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase I will also assess the scale limitations of such methods, develop common data formats, establish “use cases” for this catalog, and inform whether and how a potential second phase will be implemented. This specific FOA seeks applications for MorPhiC Data Analysis and Validation Centers. These Centers will develop computational models and data analysis and visualization methods to evaluate and help ensure the utility of the MorPhiC data. Separate FOAs will be issued for the two other components of MorPhiC: Data Production Research and Development Centers and a Data Resource and Administrative Coordination Center to receive, annotate, and present data for consortium and public use and to be the administrative coordinating center for the MorPhiC consortium.

Budget: NHGRI intends to commit $1.5M in FY 2022 to fund 2-3 awards. Application budgets need to reflect the actual needs of the proposed project but should not exceed $300K direct cost per year. The maximum project period is five years.

7. Leveraging Existing Data Resources for Computational Model and Tool Development to Discover Novel Candidate Mechanisms and Biomarkers for ADRD (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: RFA-NS-22-006** **Type: R01**

Application Due Date: October 26, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this funding opportunity announcement is to expand the use of existing ADRD data resources to drive, via computational model development and dissemination, new discoveries that can lead to better understanding of mechanisms, clinical risk assessment and outcomes, and to identify novel candidate biomarkers for ADRD.

Budget: NINDS intends to commit $6,500,000 total costs per year in FY 2022-2027 to fund up to five awards contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project. The maximum project period is five years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: ***Christa***
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: ***Lizél***
e: lizelk@sun.ac.za | t: +27 21 808 2105